Contact Home Twitter

Out-licensing

In order to retain greater value for the Shareholders, Zealand intends to take development programs through to clinical proof of principle before partnering, unless attractive out-licensing opportunities arise earlier.

Contact person:


Helle Størum
Director and Head of Business Development
e-mail: hst@zealandpharma.com